Bank of America
DSGN icon

Bank of America’s Design Therapeutics DSGN Stock Holding History

Bank of America’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$248K Sell
23,264
-4,182
-15% -$42.3K ﹤0.01% 5243
2025
Q4 		$257K Buy
27,446
+3,539
+15% +$27.7K ﹤0.01% 5221
2025
Q3 		$180K Sell
23,907
-718
-3% -$3.6K ﹤0.01% 6328
2025
Q2 		$83K Buy
24,625
+2,459
+11% +$9.2K ﹤0.01% 6609
2025
Q1 		$85.6K Sell
22,166
-12,994
-37% -$62K ﹤0.01% 6562
2024
Q4 		$217K Sell
35,160
-1,651
-4% -$9.56K ﹤0.01% 6081
2024
Q3 		$198K Buy
36,811
+4,527
+14% +$21.3K ﹤0.01% 6002
2024
Q2 		$108K Sell
32,284
-13,113
-29% -$51.1K ﹤0.01% 6225
2024
Q1 		$183K Sell
45,397
-40,941
-47% -$109K ﹤0.01% 5928
2023
Q4 		$229K Buy
86,338
+37,603
+77% +$86.1K ﹤0.01% 6002
2023
Q3 		$115K Sell
48,735
-29,143
-37% -$136K ﹤0.01% 6193
2023
Q2 		$491K Buy
77,878
+21,635
+38% +$132K ﹤0.01% 5294
2023
Q1 		$325K Sell
56,243
-239,617
-81% -$1.79M ﹤0.01% 5654
2022
Q4 		$3.04M Buy
295,860
+228,971
+342% +$3.1M ﹤0.01% 3876
2022
Q3 		$1.12M Buy
66,889
+38,914
+139% +$774K ﹤0.01% 4800
2022
Q2 		$391K Sell
27,975
-29,224
-51% -$395K ﹤0.01% 5602
2022
Q1 		$924K Buy
57,199
+2,262
+4% +$34.6K ﹤0.01% 5355
2021
Q4 		$1.18M Buy
54,937
+23,307
+74% +$400K ﹤0.01% 5078
2021
Q3 		$465K Buy
31,630
+25,228
+394% +$419K ﹤0.01% 5703
2021
Q2 		$127K Sell
6,402
-15,219
-70% -$384K ﹤0.01% 6380
2021
Q1 		$646K Buy
+21,621
New +$729K ﹤0.01% 5175

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bank of America's DSGN Position: Q1 2026 in Review

Bank of America reduced its Design Therapeutics (DSGN) stake by 15% in Q1 2026, selling an estimated $42.3K and leaving 23,264 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #5243.

Bank of America first reported a position in DSGN in Q1 2021 and has held it in 21 quarters since. The position peaked at $3.04M in Q4 2022. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Bank of America held 23,264 shares of Design Therapeutics worth $248K as of Q1 2026.
  • Bank of America sold 4,182 Design Therapeutics shares in Q1 2026, an estimated $42.3K.
  • Design Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5243 holding.
  • Bank of America first reported a position in Design Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Bank of America's Design Therapeutics position peaked at $3.04M in Q4 2022.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.